UBS Boosts Viatris to Buy, Price Target Raised to $18 Sparks 6.4% Rally
Shares of medication company Viatris rose 6.4% after UBS upgraded its rating to Buy and lifted its price target to $18 from $11. The stock has gained 24.8% year-to-date and hit a 52-week high while exhibiting volatility after Q4 misses and regulatory challenges at its Indore facility.
1. UBS Upgrade and Price Target Increase
Shares of Viatris jumped 6.4% after UBS upgraded its rating from Neutral to Buy and raised its price target to $18 from $11, signaling renewed investor confidence in the company’s pipeline and growth trajectory.
2. Stock Performance and Volatility Trends
Viatris shares have climbed 24.8% since the start of the year, reaching a 52-week high, but remain volatile with ten intrayear moves exceeding 5%, reflecting sensitivity to analyst actions and company updates.
3. Q4 Misses and Regulatory Headwinds
In the prior quarter, Viatris missed expectations for sales, earnings and operating income, and faces ongoing regulatory challenges at its Indore facility projected to cut revenue by about $500 million and adjusted EBITDA by $385 million.